Dr. Miroslav Reljanovic is re designated as Executive Vice Chairman of the Board of the company effect from 1 July 2017. He is a medical doctor and a board-certifed neurologist. Whilst practicing as a physician in a large WHO Collaborating Centre in Zagreb, he was the clinical investigator in numerous Phase II and III studies in the field of neurology and a consultant to various pharmaceutical companies. In 1997 Miro founded Ergomed and he introduced the novel Study Site Coordination model as an intrinsic part of the conduct of clinical studies. This model became a landmark of the Ergomed approach to clinical research, which is paramount to provide high quality. Miro successfully introduced the ?rst European innovative co-development business model and he has completed several transactions with European and North American listed biopharmaceutical companies. Together with co-founder Elliot Brown, MB, MRCGP, FFPM, a well-known international expert in drug safety, Miro started Prime Vigilance in 2008, which soon became a leading specialist vendor of contracted pharma covigilance services to the pharmaceutical industry.

clinical investigations, Medical feild, neurology, field of neurology